-
Article
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase
Virus-directed enzyme prodrug therapy (VDEPT) utilising cytosine deaminase (CD) converts 5-fluorocytosine (5-FC) into the chemotherapy agent, 5-fluorouracil (5-FU), and has entered into a clinical trial for me...
-
Article
Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
Expression of the E. coli enzyme nitroreductase (NTR) in tumour cells enables them to activate the prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide), leading to inter- strand DNA crosslinking and cell de...
-
Article
Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells
The majority of tumour cells do not express immune costimulatory molecules and this may account for their inability to stimulate directly an antitumour T cell response. Here we report on the construction of a ...
-
Article
Anti-proliferative activity and mechanism of action of titanocene dichloride
Development of resistance to cytotoxic agents is a major limitation to their clinical use. Novel compounds are synthesized with a view to develop non-cross-resistant, less toxic and more potent activity. The d...
-
Article
A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases
Forty patients with unresectable colorectal metastases confined to the liver were evaluated in a phase II study. 5-Fluorouracil (5-FU) was delivered via a surgically placed hepatic artery catheter. Patients re...
-
Article
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
A novel peritoneal carrier solution, Icodextrin 20 (7.5%), has allowed exploration of prolonged, intraperitoneal (i.p.) infusion of the cytotoxic drug 5-fluorouracil (5-FU). A phase I and pharmacokinetic study...
-
Article
Delivering cancer care: a model from the West Midlands
It would seem that time, tide and wind are favourably set for a shift in the organisation of cancer services. Let us test the hypotheses outlined in this brief paper and see if these changes will bring about d...
-
Article
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks,...
-
Article
A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases
Regional chemotherapy, delivered via the hepatic artery, may significantly increase tumour response rates in patients with colorectal liver metastases. However, survival is limited by extrahepatic disease prog...
-
Article
Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma
Five patients with advanced colorectal and gastric carcinoma with peritoneal deposits were treated by continuous weekdays intraperitoneal (i.p.) instillation of 5-fluorouracil (5-FU) 200 mg m-2 day-1 in a nove...
-
Article
Hepatic arterial chemotherapy for metastatic colorectal carcinoma
In this review, the rationale of regional chemotherapy for treatment of hepatic metastases in advanced colorectal carcinoma is discussed. Pharmacokinetic principles and early clinical experience of hepatic art...
-
Article
Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin
Growth of cells in vitro in the presence of fatty acids can alter the membrane composition and hence fluidity and permeability. Exposure of both doxorubicin (2780AD) and cisplatin (2780CP) resistant human ovar...
-
Article
Is there a relationship between regional microsphere distribution and hepatic arterial blood flow?
The relationship between hepatic arterial albumin microsphere distribution and hepatic arterial blood flow and the effects of regional angiotensin II were studied in a rat liver metastases model. Hooded-Lister...
-
Article
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma
We describe melphalan pharmacokinetics in 26 patients treated by isolated limb perfusion (ILP). Group A (n = 11) were treated with a bolus of melphalan (1.5 mg kg-1), and in a phase I study the dose was increa...
-
Article
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases
A phase I study was undertaken in order to establish the maximum tolerated dose of intra-hepatic arterial 5-fluorouracil (5-FU) when given in combination with systemic folinic acid. Patients with colorectal li...
-
Article
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer
A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and n...
-
Article
An in vivo assessment of adriamycin-loaded albumin microspheres
-
Article
A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid
Recent clinical trials have suggested that a combination of folinic acid and 5-fluorouracil (5-FU) may improve response rates and survival in patients with advanced colorectal cancer. However, this regimen has...
-
Article
Regional delivery of microspheres to liver metastases: the effects of particle size and concentration on intrahepatic distribution
There is increasing interest in the use of microspheres, loaded with chemotherapeutic agents, for regional therapy to hepatic metastases. It is necessary to deliver these particles predominately to tumour rath...
-
Article
Phase I and pharmacokinetic study of D-verapamil and doxorubicin
The calcium antagonist verapamil (a mixture of D- and L-racemers) is a potent modulator of the multi-drug resistance phenotype in vitro at a concentration of 6 microM. Clinical studies have shown dose-limiting...
